Prof. dr. Christophe Moreno, M.D.
Christophe is a professor in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is an important consultant to the NASH Clinical team.
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno
On the 19th of September, we presented the 9th webinar of our NASH Webinar Series. During this webinar, speaker Professor Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only causes NAFLD but can also serve ...
On May 23, we presented the webinar: Why NASH trials frequently fail and how to improve them Guest speaker: Professor Manuel Castro Cabezas Host: Professor Diederick E. Grobbee Fill in the form and watch the replay: ...
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program. During this presentat...